Abiopharma

Enliven Therapeutics Announces Closing of Public Offering of Common Stock and Pre-Funded Warrants and Full Exercise of the Underwriters Option to Purchase Additional Shares

New Form DEF 14A - Hoth Therapeutics, Inc. Filed: 2025-06-16 AccNo: 0001213900-25-054759 Size: 3 MB

New Form 4 - Tarsus Pharmaceuticals, Inc. Filed: 2025-06-16 AccNo: 0001819790-25-000094 Size: 11 KB

New Form 144 - Penumbra Inc Filed: 2025-06-16 AccNo: 0001950047-25-004323 Size: 6 KB

New Form 4 - SANGAMO THERAPEUTICS, INC Filed: 2025-06-16 AccNo: 0001415889-25-017371 Size: 7 KB

New Form 4 - SANGAMO THERAPEUTICS, INC Filed: 2025-06-16 AccNo: 0001415889-25-017372 Size: 7 KB

New Form 4 - SANGAMO THERAPEUTICS, INC Filed: 2025-06-16 AccNo: 0001415889-25-017374 Size: 7 KB

New Form 144 - GILEAD SCIENCES, INC. Filed: 2025-06-16 AccNo: 0001950047-25-004321 Size: 8 KB

New Form 4 - SANGAMO THERAPEUTICS, INC Filed: 2025-06-16 AccNo: 0001415889-25-017369 Size: 7 KB

New Form 4 - SANGAMO THERAPEUTICS, INC Filed: 2025-06-16 AccNo: 0001415889-25-017373 Size: 8 KB

New Form 4 - Tarsus Pharmaceuticals, Inc. Filed: 2025-06-16 AccNo: 0001819790-25-000092 Size: 11 KB

New Form 4 - Tarsus Pharmaceuticals, Inc. Filed: 2025-06-16 AccNo: 0001819790-25-000091 Size: 11 KB

Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trials for its SPY002 Program, its Novel Half-Life Extended Anti-TL1A Antibodies on June 17, 2025

Avadel Announces Grant of Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Streamline Health® Reports Fiscal First Quarter 2025 Financial Results